Creative Planning’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$48.9M Buy
109,524
+9,011
+9% +$4.2M 0.03% 223
2025
Q4
$45.6M Buy
100,513
+5,649
+6% +$2.43M 0.03% 217
2025
Q3
$37.2M Buy
94,864
+7,690
+9% +$3.21M 0.03% 242
2025
Q2
$38.8M Sell
87,174
-1,666
-2% -$768K 0.03% 214
2025
Q1
$43.1M Buy
88,840
+9,370
+12% +$4.37M 0.04% 190
2024
Q4
$32M Sell
79,470
-997
-1% -$462K 0.03% 209
2024
Q3
$37.4M Buy
80,467
+1,350
+2% +$648K 0.04% 183
2024
Q2
$37.1M Buy
79,117
+3,998
+5% +$1.74M 0.04% 174
2024
Q1
$31.4M Buy
75,119
+1,883
+3% +$796K 0.03% 189
2023
Q4
$29.8M Sell
73,236
-48,292
-40% -$17.8M 0.06% 187
2023
Q3
$42.3M Buy
121,528
+52,243
+75% +$18.3M 0.06% 140
2023
Q2
$24.4M Buy
69,285
+2,589
+4% +$872K 0.03% 193
2023
Q1
$21M Buy
66,696
+1,236
+2% +$371K 0.03% 208
2022
Q4
$18.9M Buy
65,460
+56,673
+645% +$17.3M 0.03% 226
2022
Q3
$2.54M Sell
8,787
-4,318
-33% -$1.24M ﹤0.01% 615
2022
Q2
$3.69M Buy
13,105
+7,280
+125% +$1.95M 0.01% 539
2022
Q1
$1.52M Sell
5,825
-683
-10% -$162K ﹤0.01% 811
2021
Q4
$1.43M Sell
6,508
-32,516
-83% -$6.32M ﹤0.01% 798
2021
Q3
$7.08M Buy
39,024
+6,914
+22% +$1.35M 0.01% 333
2021
Q2
$6.47M Buy
32,110
+25,348
+375% +$5.3M 0.01% 345
2021
Q1
$1.45M Buy
6,762
+359
+6% +$78.9K ﹤0.01% 851
2020
Q4
$1.51M Sell
6,403
-29
-0.5% -$6.65K ﹤0.01% 775
2020
Q3
$1.75M Buy
6,432
+2,468
+62% +$681K ﹤0.01% 612
2020
Q2
$1.15M Buy
3,964
+1,013
+34% +$275K ﹤0.01% 695
2020
Q1
$702K Sell
2,951
-564
-16% -$129K ﹤0.01% 789
2019
Q4
$769K Buy
3,515
+134
+4% +$27.1K ﹤0.01% 907
2019
Q3
$573K Sell
3,381
-187
-5% -$33.1K ﹤0.01% 991
2019
Q2
$654K Sell
3,568
-423
-11% -$73.9K ﹤0.01% 937
2019
Q1
$734K Sell
3,991
-261
-6% -$48.2K ﹤0.01% 857
2018
Q4
$705K Buy
4,252
+253
+6% +$43.8K ﹤0.01% 808
2018
Q3
$771K Buy
3,999
+491
+14% +$87.4K ﹤0.01% 867
2018
Q2
$596K Sell
3,508
-132
-4% -$20.5K ﹤0.01% 978
2018
Q1
$593K Sell
3,640
-723
-17% -$118K ﹤0.01% 998
2017
Q4
$654K Buy
4,363
+513
+13% +$76K ﹤0.01% 923
2017
Q3
$585K Buy
3,850
+134
+4% +$20.2K ﹤0.01% 973
2017
Q2
$479K Buy
3,716
+917
+33% +$110K ﹤0.01% 1033
2017
Q1
$306K Sell
2,799
-2,265
-45% -$199K ﹤0.01% 1245
2016
Q4
$373K Sell
5,064
-490
-9% -$39.9K ﹤0.01% 1077
2016
Q3
$484K Buy
5,554
+305
+6% +$28.8K ﹤0.01% 914
2016
Q2
$451K Buy
5,249
+102
+2% +$8.81K ﹤0.01% 828
2016
Q1
$409K Sell
5,147
-189
-4% -$17.1K ﹤0.01% 832
2015
Q4
$671K Buy
5,336
+1,945
+57% +$235K 0.01% 634
2015
Q3
$353K Buy
+3,391
New +$436K ﹤0.01% 893
2015
Q2
Sell
-3,045
Closed -$359K 2989
2015
Q1
$359K Sell
3,045
-37
-1% -$4.43K ﹤0.01% 903
2014
Q4
$366K Buy
3,082
+1,819
+144% +$205K ﹤0.01% 836
2014
Q3
$142K Sell
1,263
-646
-34% -$61.5K ﹤0.01% 1255
2014
Q2
$181K Buy
1,909
+547
+40% +$38.4K ﹤0.01% 1085
2014
Q1
$96K Buy
1,362
+110
+9% +$8.71K ﹤0.01% 1426
2013
Q4
$93K Buy
1,252
+8
+0.6% +$557 ﹤0.01% 1234
2013
Q3
$94K Buy
1,244
+374
+43% +$29.8K ﹤0.01% 1153
2013
Q2
$70K Buy
+870
New +$64.1K ﹤0.01% 1191

Other funds holding VRTX

Creative Planning's VRTX Position: Q1 2026 in Review

Creative Planning increased its Vertex Pharmaceuticals (VRTX) stake by 9% in Q1 2026, buying an estimated $4.2M and bringing the position to 109,524 shares worth $48.9M. The position accounts for 0.03% of the portfolio, ranked #223.

Creative Planning first reported a position in VRTX in Q2 2013 and has held it in 51 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Creative Planning held 109,524 shares of Vertex Pharmaceuticals worth $48.9M as of Q1 2026.
  • Creative Planning bought 9,011 Vertex Pharmaceuticals shares in Q1 2026, an estimated $4.2M.
  • Vertex Pharmaceuticals made up 0.03% of Creative Planning's portfolio in Q1 2026, its #223 holding.
  • Creative Planning first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.